12:00 AM
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Rencarex girentuximab: Additional Phase III data

Wilex reported additional data from a subgroup analysis of the double-blind, international Phase III ARISER trial in 864 clear cell RCC patients at the American Society of Clinical Oncology meeting in Chicago. In patients with a high CAIX score (>=2.6 points) (n=151), IV Rencarex led to a median DFS of 73.6 months vs. 51.2 months for placebo (HR=0.54, p=0.02). The company said the improvement in DFS was even greater in patients with a high CAIX score who received >=8 consecutive doses of Rencarex (n=139; HR=0.51, p=0.007). In patients...

Read the full 420 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >